Indapta Therapeutics
About Indapta Therapeutics
Develops an off-the-shelf, allogeneic natural killer (NK) cell therapy using FcRγ-deficient g-NK cells derived from healthy donors to treat hematologic and solid tumors. This therapy enhances antibody-dependent cell-mediated cytotoxicity (ADCC) when combined with FDA-approved monoclonal antibodies, offering a potent alternative to autologous T-cell therapies for patients with relapsed or refractory cancers.
```xml <problem> Current cancer and autoimmune disease therapies are often ineffective and cause significant side effects. Existing immunotherapies, such as autologous T-cell therapies, have limitations in addressing these diseases. </problem> <solution> Indapta Therapeutics is developing an off-the-shelf, allogeneic natural killer (NK) cell therapy to treat both cancer and autoimmune diseases. Their platform uses a subset of NK cells deficient in the FceR1g protein, known as g-NK cells, derived from healthy donors. These g-NK cells exhibit enhanced cytotoxicity against cancer cells and autoreactive T and B cells. Indapta's therapy aims to overcome the limitations of current treatments by providing a readily available cellular immunotherapy that can be used alone or in combination with FDA-approved monoclonal antibodies to improve patient outcomes. The company's proprietary process expands g-NK cells without artificial genetic engineering, yielding a highly potent product. </solution> <features> - Utilizes allogeneic, FcRγ-deficient natural killer (g-NK) cells derived from healthy donors - Exhibits increased cytokine secretion, higher levels of cytolytic enzymes, and a more favorable metabolic profile compared to conventional NK cells - Demonstrates markedly higher antibody-dependent cell-mediated cytotoxicity (ADCC) - Proprietary expansion process yields a highly potent product without genetic engineering - Designed for combination with FDA-approved monoclonal antibodies - Investigational products are currently in Phase 1 clinical trials for relapsed/refractory non-Hodgkin’s lymphoma, multiple myeloma, and multiple sclerosis </features> <target_audience> The primary target audience includes patients with hematologic and solid tumors, as well as individuals suffering from autoimmune diseases such as multiple sclerosis, who have not responded to existing therapies. </target_audience> ```
What does Indapta Therapeutics do?
Develops an off-the-shelf, allogeneic natural killer (NK) cell therapy using FcRγ-deficient g-NK cells derived from healthy donors to treat hematologic and solid tumors. This therapy enhances antibody-dependent cell-mediated cytotoxicity (ADCC) when combined with FDA-approved monoclonal antibodies, offering a potent alternative to autologous T-cell therapies for patients with relapsed or refractory cancers.
Where is Indapta Therapeutics located?
Indapta Therapeutics is based in San Francisco, United States.
When was Indapta Therapeutics founded?
Indapta Therapeutics was founded in 2017.
How much funding has Indapta Therapeutics raised?
Indapta Therapeutics has raised 111500000.
- Location
- San Francisco, United States
- Founded
- 2017
- Funding
- 111500000
- Employees
- 22 employees